Fig. 1

High expression of PDZK1 is associated with recurrence of HCC treated with oxaliplatin. A The flowchart of gene screening. The left side of the Venny diagram represents the differentially expressed genes (DEGs) of oxaliplatin-resistant MHCC97H (n = 3) or control MHCC97H (n = 3) in GSE51951 database, while the right side represents the DEGs of the HCC group (n = 47) and its paired normal (n = 47) in TCGA-LIHC database. Both databases were screened based on 丨fold change丨 ≥ 1.5 and p < 0.001, resulting in 8 DEGs. Then, the relationship between the expression of the 8 genes mentioned above and RFS in HCC patients of CLCA database was analyzed, and PDZK1 was obtained. B PDZK1 expression in oxaliplatin-resistant (n = 3) and control MHCC97H HCC cell in GSE51941 database. Unpaired t-test, **p < 0.01. C PDZK1 expression in HCC group (n = 47) and its paired normal (n = 47) in TCGA-LIHC database. Paired t-test, **** p < 0.0001. D Kaplan-Meier plot for relapse-free survival (RFS) based on PDZK1 mRNA expression of HCC patients after treatment in CLCA database (p < 0.05, log-rank test). E The screening process for clinical cases of HCC treated with oxaliplatin included in this study. F Abdominal CT images and immunohistochemical schematic of PDZK1 protein expression for HCC non-recurrence and recurrence after OXA treatment. G Statistical chart of PDZK1 immunohistochemical scores for non recurrent and recurrent OXA-treated HCC. Unpaired t-test, *p < 0.05. H Distribution of different treatment outcomes for non-recurrent and recurrent OXA-treated HCC. Fisher’s exact test, **p < 0.01. I The relationship between PDZK1 protein expression and relapse-free survival (RFS) of OXA-treated HCC.